CONX News 0.2800 Corgenix Med Corp (CONX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Corgenix Med Corp (CONX) 0.2800 $CONX

Corgenix, Tulane and Viral Hemorrhagic Fever Consortium Publish Promising Results from Lassa Fever Trial
Business Wire - Tue Apr 01, 8:15AM CDT
A Corgenix Medical (OTCBB:CONX) rapid diagnostic test (RDT) for the dangerous Lassa fever virus has demonstrated the ability to quickly detect the virus, responsible for the deaths of thousands and infection of hundreds of thousands in West Africa each year. That's according to the results of the five-year trial Lassa Fever in Post-Conflict Sierra Leone published in the PLOS Neglected Tropical Diseases Journal.

Corgenix and Research Partners to Expand Ebola Virus Testing Capabilities in Sierra Leone
Business Wire - Thu Mar 27, 8:15AM CDT
An outbreak of the deadly Ebola virus in West Africa has prompted Corgenix Medical Corporation (OTCBB:CONX) to extend its existing viral hemorrhagic fever (VHF) rapid test development to include the Ebola virus. Corgenix has already developed and CE marked a rapid test for the Lassa fever virus, another member of the VHF group of viruses.

Corgenix Board of Directors Announces Exploration of Strategic Alternatives
Business Wire - Wed Mar 12, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that the Company's Board of Directors has decided to explore strategic alternatives to enhance value for shareholders. These alternatives could include, among others, possible joint ventures, strategic partnerships or alliances, a sale of the Company or other possible transactions.

Corgenix Medical Corporation posts higher net income of USD178,497 for Q2 fiscal 2014
M2 - Fri Feb 14, 3:06AM CST
Diagnostic test kits company Corgenix Medical Corporation (OTC BB:CONX) reported on Thursday its net income of USD178,497 for second quarter fiscal 2014.

Corgenix Reports Second Quarter Fiscal 2014 Financial Results
Business Wire - Thu Feb 13, 8:15AM CST
Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, today filed its second quarter Form 10-Q and reported its financial results. The report disclosed that the company's revenues and net income increased both for the quarter and year to date. Some of the results highlighted by the report are as follows:

Corgenix to Host Conference Call to Discuss Second Quarter Results
Business Wire - Tue Feb 04, 8:15AM CST
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, February 13, 2014, at 4:00 p.m. EST to discuss the Company's financial and operating performance for its quarter ended December 31, 2013, and the status of the Company's product development and marketing activities.

Corgenix Announces Filing of 510(k) Premarket Notification for FDA Clearance of TxBCardio(TM) Assay
Business Wire - Mon Dec 16, 8:15AM CST
Corgenix Medical Corporation (OTC BB: CONX.OB) announced today that in collaboration with Randox Laboratories, the first premarket notification has been filed with the U.S. Food and Drug Administration pursuant to Section 510(k) of the U.S. Federal Food, Drug and Cosmetic Act for the TxBCardio(TM) immunoturbidimetric (IT) assay.

Corgenix Medical Corp posts lower net income of USD84,000, but higher revenue of USD2.88m in Q1 fiscal 2014
M2 - Tue Dec 03, 7:16AM CST
Diagnostic test kits company Corgenix Medical Corporation (OTCBB:CONX.OB) on Monday reported net income of USD84,000 for the quarter ended 30 September 2013.

Corgenix to Launch New Hepcidin-25 Product at the American Society of Hematology Annual Meeting
Business Wire - Mon Dec 02, 8:15AM CST
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that it will launch the Research-Use-Only (RUO) Hepcidin-25 Chemiluminescent Direct ELISA test kit at the 55th Annual Meeting of the American Society of Hematology (ASH(R)) at the Ernest N. Morial Convention Center in New Orleans. The test kit is based on technology originally developed at Eli Lilly and Company and licensed for further development by Corgenix.

Corgenix Medical Corporation & Zalgen Labs partnership to develop diagnostic test for common virus associated with birth defects
M2 - Tue Nov 19, 4:22AM CST
Diagnostic test kits company Corgenix Medical Corporation (OTC BB:CONX) reported on Monday the launch of a collaboration agreement for "next generation" rapid test kit for the early detection of active cytomegalovirus (CMV) infections.

Corgenix Inks Collaborative Diagnostic Test Development Deal with Zalgen Labs
Business Wire - Mon Nov 18, 8:15AM CST
Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that it has entered into a collaboration agreement with Zalgen Labs, a biotechnology company dedicated to the development of multiple diagnostic testing platforms and immunotherapeutics for high impact neglected infectious diseases.

Corgenix's net income down by 57.6% in Q1 fiscal 2014
M2 - Fri Nov 15, 4:57AM CST
Corgenix Medical Corporation (OTCBB:CONX.OB), a developer and marketer of diagnostic test kits, on Thursday reported net income of USD0.084m, for the first quarter of fiscal 2014, ended 30 September 2013.

Corgenix Reports First Quarter Fiscal 2014 Financial Results
Business Wire - Thu Nov 14, 8:14AM CST
Corgenix Medical Corporation (OTCBB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today filed its fiscal quarter Form 10-Q and reported financial results. The report disclosed that the company achieved record operating results for the quarter ended September 30, 2013.

Corgenix Files Concurrent de novo 510(k) Pre-Market Notification for FDA Clearance of its Hyaluronic Acid (HA) Test Kit
Business Wire - Tue Nov 12, 9:41AM CST
Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, announced today it has filed pre-market notification to the FDA pursuant to Section 510(k) of the U.S. Federal Food, Drug and Cosmetic Act for its Hyaluronic Acid (HA) ELISA Test Kit.

Study: Aspirin Ineffective in 20 Percent of Heart Disease Patients
Business Wire - Thu Nov 07, 8:15AM CST
A major new study conducted in Ireland found that 20 percent of patients with established heart disease were not adequately protected by aspirin. Corgenix Medical Corporation, developers of the AspirinWorks(R) Test for aspirin effect, said the study adds more evidence to the importance of accurately measuring aspirin response by measuring levels of the biomarker thromboxane.

Corgenix Medical Corporation schedules conference call for 14 November 2013 to discuss Q1 results
M2 - Wed Nov 06, 6:05AM CST
Corgenix Medical Corporation (OTC Markets:CONX) stated on Tuesday that it will host a conference call on 14 November 2013 at 16:00 EST.

Corgenix to Host Conference Call to Discuss First Quarter Results
Business Wire - Tue Nov 05, 8:15AM CST
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, November 14, 2013, at 4:00 PM EST to discuss the Company's financial and operating performance for its quarter ended September 30, 2013, and the status of the Company's product development and marketing activities.

Corgenix Medical Corporation enters into diagnostic test development partnership with Health Diagnostic Laboratory
M2 - Tue Oct 29, 8:40AM CDT
Diagnostic test kits company Corgenix Medical Corporation (Other OTC:CONX) reported on Monday the launch of a strategic partnership to advance the development of its clinical Laboratory Developed Test (LDT) with Health Diagnostic Laboratory Inc (HDL Inc).

Corgenix Announces Diagnostic Test Development Partnership with Health Diagnostic Laboratory, Inc.
Business Wire - Mon Oct 28, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced a strategic partnership with Health Diagnostic Laboratory, Inc. (HDL, Inc.) for the development of a clinical Laboratory Developed Test (LDT). The LDT would be based on Corgenix' patented proprietary atherosclerosis biomarker technology for potential use in assessing heart disease risk.

Corgenix to Host Conference Call to Discuss Fiscal 2013 Results
Business Wire - Wed Sep 18, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Monday, September 30, 2013, at 4:00 PM EDT to discuss the Company's financial and operating performance for its fiscal year ended June 30, 2013, and the status of the Company's product development and marketing activities.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

APEC's Shared-Prosperity Message Needs More Detail

Updated Category News Views 13

Geese make handsome symbols, but markets cannot underwrite a metaphor. The Nov. 18, 2026 report from Xinhua News Agency looks back to remarks Chinese President Xi Jinping made 12 years ago, when he used swan geese to urge APEC economies toward greater cooperation and a new collective flight. Its present-day message is plainly hopeful: the APEC family is moving across the...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 119

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 131

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
FULC, DSGR and OPCH Deals Draw Fresh Shareholder Scrutiny

Updated Category News Views 85

Three proposed transactions have drawn the kind of legal glare that makes shareholders sit up and check the fine print twice. On November 18, 2026, Halper Sadeh LLC said it was investigating deals involving Fulcrum Therapeutics, Distribution Solutions Group, and Option Care Health for possible federal securities-law violations or fiduciary-duty breaches. That is not a...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 130

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading
Redseer's $5M Bet on Faster MENA Decision Intelligence

Updated Category News Views 53

Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...

Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem

Updated Category News Views 28

Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 19

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
Gozney Brings in Armin Boehm for a Global Growth Push

Updated Category News Views 35

A pizza oven company has just made a very grown-up management move. Gozney appointed Armin Boehm as Global President, effective from October 31, putting an experienced consumer-brand operator beside founder, designer and CEO Tom Gozney at a moment when the business says it is becoming a global omnichannel operation. This is not the sort of announcement that comes with...

Continue Reading
Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 196

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading

Top 5 Most Recently Viewed Articles

Securities Fraud Investigation Casts Shadow on Driven Brands

Updated Category News Views 331

The Unfolding Drama Surrounding Driven Brands Out of nowhere, the waters are getting choppy for Driven Brands Holdings, and it’s not just a casual dip; more like a tsunami warning. Ademi LLP is cranking up the heat with an investigation into possible securities fraud that’s got investors scratching their heads and probably running for cover. What’s the Big Deal?...

Continue Reading
Info-Tech Research Group Expands Focus in Asia-Pacific Markets

Updated Category News Views 292

Info-Tech Research Group Expands Its Global Footprint Info-Tech Research Group has recently expanded its global presence by launching a new office in Singapore while significantly ramping up investments in New Zealand. This strategic move enables the firm to provide more localized, outcome-driven support to IT leaders throughout Southeast Asia and the Australia-New...

Continue Reading
Laramide Resources' Strategic Exploration Plans in Kazakhstan

Updated Category News Views 144

Exploration Drilling Plans by Laramide Resources Laramide Resources Ltd., a leading organization in uranium exploration, has identified multiple promising targets within its Chu-Sarysu Project. This initiative is set to take place in a mineral-rich area renowned for its potential to yield significant deposits of uranium and other valuable minerals like rare earth elements...

Continue Reading
Stravito Unveils AI Personas for Accelerated Market Insights

Updated Category News Views 311

Stravito Introduces AI Personas for Enhanced Market Positioning Stravito supports brands in rapidly validating their ideas using advanced AI technology. In a dynamic market environment, Stravito has launched an initiative designed to drastically improve the speed and reliability of idea testing for brands. This revolutionary tool, known as Stravito AI Personas, transforms...

Continue Reading
Duni Introduces Innovative Take-Away Series Boosting Sustainability

Updated Category News Views 245

Duni Introduces Innovative Take-Away Series Boosting Sustainability Duni is excited to unveil a fresh series of take-away packaging that represents a significant leap towards sustainability. The company has developed new packaging solutions that feature a grey plastic base, which can significantly enhance recycling efforts compared to traditional black plastic. This move...

Continue Reading